Chronic Lymphocytic Leukemia: VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
Acute Myeloid Leukemia: VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Sign Out